{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:57:40Z","timestamp":1789721860068,"version":"4.0.1"},"reference-count":60,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background: Respiratory Syncytial Virus is a predominant source of morbidity and mortality, particularly among babies, the elderly, and immunocompromised patients. Recent developments in RSV vaccines, approved by the FDA for high-risk groups, have highlighted the necessity for post-marketing surveillance to evaluate their real-world safety and efficacy. Method: This study utilized data from the Vaccine Adverse Event Reporting System (VAERS) covering RSV vaccine administration between 2023 and May 2025. The VAERS database reported data on vaccine types, including Arexvy\u00ae, Abrysvo\u00ae, and mRESVIA\u00ae was analyzed for adverse events and vaccination errors. The demographic information, vaccination trends, and hospitalizations post-vaccination among the vaccinated individuals were accessed. Results: The analysis revealed that the most common adverse events were mild, such as injection site pain, erythema, fatigue, and extremity pain. The data also showed a gradual increase in hospitalization rates from 4.8% in 2023 to 7.5% in 2025. Vaccination errors, including inappropriate administration during pregnancy and excess doses, were also observed. A notable trend was the growing proportion of patients who experienced no adverse events, with the highest rate of symptom-free reports seen in 2025 (25.9%). Conclusions: RSV vaccines demonstrate a generally acceptable safety profile based on post-marketing surveillance data. However, the observed increase in hospitalization rates, vaccination errors, and pregnancy-related outcomes warrants continued active surveillance and cautious interpretation.<\/jats:p>","DOI":"10.3390\/diseases14010029","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:52:17Z","timestamp":1767963137000},"page":"29","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Evidence Evaluation of Respiratory Syncytial Virus (RSV) Vaccines: Deep Dive into Vaccine Adverse Events Reporting System"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-2468","authenticated-orcid":false,"given":"Thamir M.","family":"Alshammari","sequence":"first","affiliation":[{"name":"Department of Clinical Practice, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia"},{"name":"Pharmacy Practice Research Unit, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed K.","family":"Alshammari","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care Administration, Research and Studies Unit at Rafha General Hospital, Northern Border Healthcare Cluster, Rafha 76312, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind M.","family":"Alosaimi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services Administration, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 12211, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Anastassopoulou, C., Medi\u0107, S., Ferous, S., Boufidou, F., and Tsakris, A. (2025). Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines. Vaccines, 13.","DOI":"10.3390\/vaccines13020097"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"ofac300","DOI":"10.1093\/ofid\/ofac300","article-title":"Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis","volume":"9","author":"McLaughlin","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40266-024-01118-9","article-title":"Respiratory syncytial virus infection in older adults: An update","volume":"41","author":"Alfano","year":"2024","journal-title":"Drugs Aging"},{"key":"ref_4","unstructured":"Jain, H., Schweitzer, J.W., and Justice, N.A. (2025, May 31). Respiratory Syncytial Virus Infection in Children, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459215\/."},{"key":"ref_5","first-page":"331","article-title":"Respiratory syncytial virus: A comprehensive review of transmission, pathophysiology, and manifestation","volume":"15","author":"Kaler","year":"2023","journal-title":"Cureus"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Matias, G., Taylor, R., Haguinet, F., Schuck-Paim, C., Lustig, R., and Shinde, V. (2017). Estimates of hospitalization attributable to influenza and RSV in the US during 1997\u20132009, by age and risk status. BMC Public Health, 17.","DOI":"10.1186\/s12889-017-4177-z"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13052-021-01148-8","article-title":"Epidemiology and prevention of respiratory syncytial virus infections in children in Italy","volume":"47","author":"Azzari","year":"2021","journal-title":"Ital. J. Pediatr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.289.2.179","article-title":"Mortality associated with influenza and respiratory syncytial virus in the United States","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jpids\/piz011","article-title":"Respiratory syncytial virus\u2013associated outpatient visits among children younger than 24 months","volume":"8","author":"Lively","year":"2019","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1883379","DOI":"10.1080\/21645515.2021.1883379","article-title":"Burden of severe bronchiolitis in children up to 2 years of age in Spain from 2012 to 2017","volume":"18","author":"Walter","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Fairbank, R. (2022). RSV wave hammers hospitals\u2014But vaccines and treatments are coming. Nature, epub ahead of print.","DOI":"10.1038\/d41586-022-04434-5"},{"key":"ref_13","unstructured":"Food and Drug Administration (2025, May 31). AREXVY, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/arexvy."},{"key":"ref_14","unstructured":"Food and Drug Administration (2025, May 31). ABRYSVO, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/abrysvo."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","article-title":"Use of respiratory syncytial virus vaccines in adults aged \u2265 60 years: Updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024","volume":"73","author":"Britton","year":"2024","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.15585\/mmwr.mm7241e1","article-title":"Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus\u2013associated lower respiratory tract disease in infants: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023","volume":"72","year":"2023","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMoa2106062","article-title":"Prefusion F protein\u2013based respiratory syncytial virus immunization in pregnancy","volume":"386","author":"Center","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/infdis\/jiad024","article-title":"Safety and immunogenicity of an investigational respiratory syncytial virus vaccine (RSVPreF3) in mothers and their infants: A phase 2 randomized trial","volume":"228","author":"Bebia","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_19","first-page":"e68349","article-title":"Use of the Abrysvo Vaccine in Pregnancy to Prevent Respiratory Syncytial Virus in Infants: A Review","volume":"16","author":"Patel","year":"2024","journal-title":"Cureus"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wang, X., Kong, L., Liu, X., Wu, P., Zhang, L., and Ding, F. (2025). Effectiveness of nirsevimab immunization against RSV infection in preterm infants: A systematic review and meta-analysis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1581970"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.5694\/mja2.52671","article-title":"Respiratory syncytial virus preventives for children in Australia: Current landscape and future directions","volume":"222","author":"Barnett","year":"2025","journal-title":"Med. J. Aust."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S2213-2600(24)00246-7","article-title":"Early-life respiratory syncytial virus disease and long-term respiratory health","volume":"12","author":"Zar","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e001618","DOI":"10.1136\/bmjresp-2023-001618","article-title":"Pulmonary sequelae in 2-year-old children after hospitalisation for respiratory syncytial virus lower respiratory tract infection during infancy: An observational study","volume":"10","author":"Verwey","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/01.aoa.0001026568.55763.c8","article-title":"Maternal RSV vaccine\u2014Weighing benefits and risks","volume":"44","author":"Rasmussen","year":"2024","journal-title":"Obstet. Anesth. Dig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/bmj.p1021","article-title":"Maternal RSV vaccine: Further analysis is urged on preterm births","volume":"381","author":"Boytchev","year":"2023","journal-title":"BMJ"},{"key":"ref_26","first-page":"101506","article-title":"Short term safety profile of respiratory syncytial virus vaccine in adults aged \u2265 60 years in Australia","volume":"56","author":"Nguyen","year":"2025","journal-title":"Lancet Reg. Health\u2013West. Pac."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(24)02150-0","article-title":"Real-world effectiveness studies of the benefit of RSV vaccines","volume":"404","author":"Branche","year":"2024","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e087850","DOI":"10.1136\/bmjopen-2024-087850","article-title":"Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: A real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System","volume":"15","author":"Alami","year":"2025","journal-title":"BMJ Open"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e2419229","DOI":"10.1001\/jamanetworkopen.2024.19229","article-title":"Perinatal Outcomes after RSV Vaccination during Pregnancy\u2014Addressing Emerging Concerns","volume":"7","author":"Regan","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.15585\/mmwr.mm7321a3","article-title":"Early safety findings among persons aged \u2265 60 years who received a respiratory syncytial virus vaccine\u2014United States, May 3, 2023\u2013April 14, 2024","volume":"73","author":"Hause","year":"2024","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","article-title":"Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023","volume":"72","author":"Melgar","year":"2023","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_32","unstructured":"Moro, P.L. (2024, January 28). Maternal RSV vaccine safety surveillance. Proceedings of the Advisory Committee on Immunization Practices Meeting, Atlanta, GA, USA."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"ref_34","unstructured":"Vaccine Adverse Event Reporting System (2025, May 31). VAERS Data Sets, Available online: https:\/\/vaers.hhs.gov\/data\/datasets.html."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0264-410X(94)90315-8","article-title":"The vaccine adverse event reporting system (VAERS)","volume":"12","author":"Chen","year":"1994","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jsps.2021.12.008","article-title":"Analyzing the US Post-marketing safety surveillance of COVID-19 vaccines","volume":"30","author":"Albalawi","year":"2022","journal-title":"Saudi Pharm. J."},{"key":"ref_37","unstructured":"Vaccine Adverse Event Reporting System (2025, May 31). VAERS DATA USE GUIDE, Available online: https:\/\/vaers.hhs.gov\/docs\/VAERSDataUseGuide_en_September2021.pdf."},{"key":"ref_38","unstructured":"(2025, May 31). Medical Dictionary for Regulatory Activities. Available online: https:\/\/www.meddra.org\/."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): Explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"561.e1","DOI":"10.1016\/j.ajog.2013.12.036","article-title":"Reports to the Vaccine Adverse Event Reporting System after hepatitis A and hepatitis AB vaccines in pregnant women","volume":"210","author":"Moro","year":"2014","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Alenzi, K.A., Alsuhaibani, D., Batarfi, B., and Alshammari, T.M. (2024). Pancreatitis with use of new diabetic medications: A real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1364110"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Thaibah, H.A., Banji, O.J., Banji, D., and Alshammari, T.M. (2025). Diabetic ketoacidosis and the use of new hypoglycemic groups: Real-world evidence utilizing the food and drug administration adverse event reporting system. Pharmaceuticals, 18.","DOI":"10.3390\/ph18020214"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Thaibah, H.A., Banji, O.J., Banji, D., Almansour, H.A., and Alshammari, T.M. (2025). Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports. Pharmaceuticals, 18.","DOI":"10.3390\/ph18070957"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Bate","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Poluzzi, E., Raschi, E., Piccinni, C., and De Ponti, F. (2012). Data mining techniques in pharmacovigilance: Analysis of the publicly accessible FDA adverse event reporting system (AERS). Data Mining Applications in Engineering and Medicine, IntechOpen.","DOI":"10.5772\/50095"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Hopstadius","year":"2013","journal-title":"Stat. Methods Med. Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Zhou, X., Ye, X., Guo, X., Liu, D., Xu, J., Hu, F., Zhai, Y., Gao, Y., Xu, X., and Dong, Z. (2021). Safety of SGLT2 inhibitors: A pharmacovigilance study from 2013 to 2021 based on FAERS. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.766125"},{"key":"ref_48","unstructured":"Awosika, A.O., and Patel, P. (2024). Respiratory Syncytial Virus Prefusion F (RSVPreF3) Vaccine. StatPearls, StatPearls Publishing."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_51","unstructured":"Consumer Affairs (2025, May 28). Population over 65 by State, U.S. Census Bureau, Available online: https:\/\/www.consumeraffairs.com\/homeowners\/elderly-population-by-state.html."},{"key":"ref_52","unstructured":"(2025, June 27). FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants Food and Drug Administration, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants?ftag=MSF0951a18."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2305478","article-title":"RSV prefusion F protein\u2013based maternal vaccine\u2014Preterm birth and other outcomes","volume":"390","author":"Dieussaert","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_54","unstructured":"World Health Organization (2025, May 31). Preterm Birth. WHO Fact Sheet. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/preterm-birth."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"127497","DOI":"10.1016\/j.vaccine.2025.127497","article-title":"Safety Monitoring of Pfizer\u2019s Respiratory Syncytial Virus Vaccine in Pregnant Women in the Vaccine Adverse Event Reporting System, 2023-2024, United States","volume":"62","author":"Moro","year":"2025","journal-title":"Vaccine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/bmj.p978","article-title":"First RSV vaccine for older adults is approved in Europe","volume":"381","author":"Wise","year":"2023","journal-title":"BMJ"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2207566","article-title":"Efficacy and safety of an Ad26. RSV. preF\u2013RSV preF protein vaccine in older adults","volume":"388","author":"Falsey","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40272-023-00598-3","article-title":"Respiratory syncytial virus prefusion F subunit vaccine: First approval of a maternal vaccine to protect infants","volume":"25","author":"Syed","year":"2023","journal-title":"Pediatr. Drugs"},{"key":"ref_59","unstructured":"(2025, May 30). AusVaxSafety Publishes Australian-First Safety Data for Arexvy RSV Vaccine. Available online: https:\/\/ausvaxsafety.org.au\/ausvaxsafety-publishes-australian-first-safety-data-arexvy-rsv-vaccine."},{"key":"ref_60","first-page":"67","article-title":"The role of community pharmacy-based vaccination in the USA: Current practice and future directions","volume":"4","author":"Bach","year":"2015","journal-title":"Integr. Pharm. Res. Pract."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/1\/29\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:56:09Z","timestamp":1767963369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/1\/29"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["diseases14010029"],"URL":"https:\/\/doi.org\/10.3390\/diseases14010029","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}